Skip to content

Evaluation Of Intravenous Ondansetron-induced Electrocardiogram changes In Postoperative Patients Compaired To Before Injection

Evaluation Of Intravenous Ondansetron-induced QT Interval changes In Postoperative Patients Compaired To Before Injection

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016070328754N1
Enrollment
60
Registered
2016-07-14
Start date
2016-07-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

General surgery. General- and plastic-surgery devices associated with adverse incidents

Interventions

Ondansetron 8 milligram intravenous infusion over a minute at a time in groups after surgery.
Diagnosis
Ondansetron 8 milligram intravenous infusion over a minute at a time in groups after surgery

Sponsors

Vice chancellor for research, Bushehr University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria : patients over thirty years with no history of heart disease and patients who did not use medication to take effect on QT Interval. Exclusion criteria: patients with electrolyte imbalance such as low potassium ; patients with a history of heart disease such as myocardial infarction and heart failure ; patients who have prolonged use of drugs affecting the QT Interval ; if the use of pain pumps containing ondansetron and the drug narcotic, patient is excluded ; patients who receive antinausea and vomiting drugs during surgery and immediately after surgery due to severe nausea and vomiting ; patients who have any dysrhythmia in ECG ; all procedures with the risk of the emergence of nausea and vomiting such as: laparoscopy, Orchiopexy, Varicocelectomy, surgery of ear, nose and throat, eye surgery (strabismus) , surgery of neurosurgery (ICP above) and any intervention in order to create hypocapnia not included in this study ; patients who experience severe nausea and vomiting in previous surgeries are not included in this study ; patients who have a history of sudden death in family members will not be enrolled in this study ; patients who have a history of liver disease and liver enzyme abnormalities were excluded.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
QTc Interval. Timepoint: The night before surgery, and 30 minutes after administration of ondansetron. Method of measurement: With electrocardiography.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHaghighi Rahmanian Ehsan

Bushehr University Of Medical Science

drrahmani@gmail.com+98 77 3345 0178

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026